These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8280517)

  • 1. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?
    Gray RP; Yudkin JS; Patterson DL
    Br Heart J; 1993 Dec; 70(6):530-6. PubMed ID: 8280517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.
    Gray RP; Yudkin JS; Patterson DL
    Br Heart J; 1993 Mar; 69(3):228-32. PubMed ID: 8461220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction.
    Sinkovic A
    Am Heart J; 1998 Sep; 136(3):406-11. PubMed ID: 9736130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.
    El Menyar AA; Altamimi OM; Gomaa MM; Fawzy Z; Rahman MO; Bener A
    J Thromb Thrombolysis; 2006 Jun; 21(3):235-40. PubMed ID: 16683215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
    Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J
    Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the fibrinolytic system components during acute myocardial infarction.
    Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
    Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; White HD; Modan M; Van de Werf F
    J Am Coll Cardiol; 1993 Sep; 22(3):707-13. PubMed ID: 8354802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Handa S; Abe S; Takahashi E; Watanabe K; Hori S; Ikeda Y
    Cardiology; 1993; 82(4):280-5. PubMed ID: 8402755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myoglobin concentration in serum as an early marker of reperfusion in patients with acute myocardial infarction after thrombolytic therapy].
    Kobusiak-Prokopowicz M; Mysiak A
    Pol Merkur Lekarski; 1997 Sep; 3(15):109-12. PubMed ID: 9461704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase.
    Nilsson JB; Boman K; Jansson JH; Nilsson T; Näslund U
    J Thromb Thrombolysis; 2008 Dec; 26(3):188-95. PubMed ID: 17721741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimised function for determining time to peak creatine kinase and creatine kinase-MB as non-invasive reperfusion indicators after thrombolytic therapy in acute myocardial infarction.
    Schwerdt H; Ozbek C; Fröhlig G; Schieffer H; Bette L
    Cardiovasc Res; 1990 Apr; 24(4):328-34. PubMed ID: 2189569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
    Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction.
    Sinkovic A
    Clin Cardiol; 2000 Jul; 23(7):486-9. PubMed ID: 10894435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free-radical activity after reperfusion in diabetic and non-diabetic patients with acute myocardial infarction.
    Gray RP; Wickens DG; Patterson DL; Yudkin JS
    Clin Sci (Lond); 1993 Nov; 85(5):549-55. PubMed ID: 8287642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAI-1 4G/5G gene polymorphism is associated with angiographic patency in ST-elevation myocardial infarction patients treated with thrombolytic therapy.
    Ozkan B; Cagliyan CE; Elbasan Z; Uysal OK; Kalkan GY; Bozkurt M; Tekin K; Bozdogan ST; Ozalp O; Duran M; Sahin DY; Cayli M
    Coron Artery Dis; 2012 Sep; 23(6):400-3. PubMed ID: 22850480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction.
    Gray RP; Patterson DL; Yudkin JS
    Arterioscler Thromb; 1993 Mar; 13(3):415-20. PubMed ID: 8443145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction.
    Juhlin P; Boström PA; Torp A; Bredberg A
    J Intern Med; 1999 May; 245(5):483-8. PubMed ID: 10363749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage.
    Haider AW; Andreotti F; Hackett DR; Tousoulis D; Kluft C; Maseri A; Davies GJ
    J Am Coll Cardiol; 1995 Sep; 26(3):662-7. PubMed ID: 7642856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.